Keybank National Association OH Decreases Stake in Edwards Lifesciences Corporation (NYSE:EW)

Keybank National Association OH reduced its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 16.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 35,939 shares of the medical research company's stock after selling 6,934 shares during the period. Keybank National Association OH's holdings in Edwards Lifesciences were worth $2,605,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alyeska Investment Group L.P. bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $49,038,000. Dynamic Advisor Solutions LLC lifted its position in shares of Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after purchasing an additional 370 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after purchasing an additional 9,188 shares during the last quarter. Simplify Asset Management Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $5,979,000. Finally, Assetmark Inc. lifted its position in shares of Edwards Lifesciences by 786.9% during the fourth quarter. Assetmark Inc. now owns 1,082 shares of the medical research company's stock worth $80,000 after purchasing an additional 960 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the transaction, the vice president owned 47,206 shares of the company's stock, valued at approximately $3,295,450.86. This trade represents a 16.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daveen Chopra sold 1,500 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the transaction, the vice president directly owned 33,496 shares of the company's stock, valued at $2,514,879.68. This represents a 4.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 40,648 shares of company stock valued at $2,998,866 in the last 90 days. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Down 0.3%

Edwards Lifesciences stock opened at $76.77 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. The firm has a market cap of $45.03 billion, a price-to-earnings ratio of 10.97, a price-to-earnings-growth ratio of 3.86 and a beta of 1.11. Edwards Lifesciences Corporation has a 1 year low of $58.93 and a 1 year high of $95.25. The firm's 50 day moving average price is $76.12 and its two-hundred day moving average price is $73.27.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The firm's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.66 earnings per share. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EW. Truist Financial reduced their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Robert W. Baird increased their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a report on Friday, April 25th. Citigroup reissued a "buy" rating and issued a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Finally, Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.